Didier Meulien

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.

Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 13, 2023

A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.

A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: January 06, 2022

Diagnostic criteria for apathy in neurocognitive disorders.

Diagnostic criteria for apathy in neurocognitive disorders.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: June 25, 2020

Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.

Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.

Journal: Psychiatry and clinical neurosciences

Published: March 04, 2020

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.

Journal: The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

Published: May 07, 2019

Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.

Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.

Journal: Alcohol and alcoholism (Oxford, Oxfordshire)

Published: April 11, 2019

Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.

Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.

Journal: JAMA psychiatry

Published: March 14, 2019

Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.

Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.

Journal: Psychiatry and clinical neurosciences

Published: December 20, 2018

Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.

Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.

Journal: European addiction research

Published: July 13, 2018

Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group.

Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: April 21, 2018

Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.

Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.

Journal: Biological psychiatry

Published: June 09, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026